Zacks Investment Research upgraded shares of XOMA Corporation (NASDAQ:XOMA) from a sell rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other equities research analysts also recently commented on XOMA. HC Wainwright started coverage on shares of XOMA Corporation in a research report on Monday, June 12th. They issued a buy rating and a $15.00 price objective on the stock. ValuEngine raised shares of XOMA Corporation from a strong sell rating to a sell rating in a research report on Wednesday, July 12th. Finally, Wedbush reissued a hold rating on shares of XOMA Corporation in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. XOMA Corporation presently has a consensus rating of Hold and a consensus price target of $14.00.
Shares of XOMA Corporation (NASDAQ XOMA) opened at 19.57 on Tuesday. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $20.84. The firm has a 50-day moving average of $11.46 and a 200 day moving average of $7.86. The firm’s market capitalization is $148.69 million.
An institutional investor recently bought a new position in XOMA Corporation stock. Stonepine Capital Management LLC bought a new stake in XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation comprises about 0.4% of Stonepine Capital Management LLC’s holdings, making the stock its 19th largest position. Stonepine Capital Management LLC owned approximately 1.17% of XOMA Corporation at the end of the most recent quarter. Institutional investors own 32.92% of the company’s stock.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with our FREE daily email newsletter.